Use of proton pump inhibitors is associated with fractures in young adults: a population-based study

Osteoporosis International

Volumn 26, Issue 10, 2015, Pages 2501-2507

  Freedberg, D E ^a   Haynes, K ^b   Denburg, M R ^c   Zemel, B S ^b   Leonard, M B ^d   Abrams, J A ^a   Yang, Y X ^b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acid suppression medications; Bone mineral density; Fracture; Histamine 2 receptor antagonists; Osteoporosis; Outcomes research; Pediatrics; Pharmacoepidemiology; Proton pump inhibitors

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; OPIATE; PROTON PUMP INHIBITOR; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; FOOT FRACTURE; FRACTURE; GENERAL PRACTICE; HAND FRACTURE; HIP FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; WRIST FRACTURE; YOUNG ADULT; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; MULTICENTER STUDY; OSTEOPOROTIC FRACTURES; PRESCHOOL CHILD; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; OSTEOPOROTIC FRACTURES; PROTON PUMP INHIBITORS; UNITED KINGDOM; YOUNG ADULT;

EID: 84942371362     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3168-0     Document Type: Article

References (38)

1. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953
2. van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA (2011) Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 127:925–935
3. Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D (2012) Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics 130:23–31
4. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC (2003) Who is using chronic acid suppression therapy and why? Am J gastroenterol 98:51–58
5. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
6. Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C (2014) Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 78:310–315
7. Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904
8. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771
9. Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W, CaMos Research G (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369
10. Martin AD, Bailey DA, McKay HA, Whiting S (1997) Bone mineral and calcium accretion during puberty. Am J Clin Nutr 66:611–615
11. Yang YX, Metz DC (2010) Safety of proton pump inhibitor exposure. Gastroenterology 139:1115–1127
12. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL (2007) Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16:393–401
13. Denburg MR, Haynes K, Shults J, Lewis JD, Leonard MB (2011) Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf 20:1138–1149
14. World Health Organization (2014) The World Health Organization child growth standards. http://www.who.int/childgrowth/en/. Accessed July 24
15. Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP (2004) Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 19:1976–1981
16. Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ (2008) The epidemiology of fractures in England. J Epidemiol Community Health 62:174–180
17. Hassall E, Kerr W, El-Serag HB (2007) Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 150:262–267, 267 e261
18. Booth N (1994) What are the Read codes? Health Libr Rev 11:177–182
19. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366
20. Lubin JH, Gail MH (1984) Biased selection of controls for case–control analyses of cohort studies. Biometrics 40:63–75
21. Cole TJ, Freeman JV, Preece MA (1998) British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 17:407–429
22. Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951–959
23. Loder RT, O’Donnell PW, Feinberg JR (2006) Epidemiology and mechanisms of femur fractures in children. J Pediatr Orthop 26:561–566
24. Liu EH, Alqahtani S, Alsaaran RN, Ho ES, Zuker RM, Borschel GH (2014) A prospective study of pediatric hand fractures and review of the literature. Pediatr Emerg Care 30:299–304
25. Palvanen M, Kannus P, Parkkari J, Pitkajarvi T, Pasanen M, Vuori I, Jarvinen M (2000) The injury mechanisms of osteoporotic upper extremity fractures among older adults: a controlled study of 287 consecutive patients and their 108 controls. Osteoporos Int: J Established Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 11:822–831
26. Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310:2435–2442
27. Recker RR (1985) Calcium absorption and achlorhydria. N Engl J Med 313:70–73
28. Merriman NA, Putt ME, Metz DC, Yang YX (2010) Hip fracture risk in patients with a diagnosis of pernicious anemia. Gastroenterology 138:1330–1337
29. Chonan O, Takahashi R, Yasui H, Watanuki M (1998) Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 44:473–481
30. Joo MK, Park JJ, Lee BJ, Kim JH, Yeon JE, Kim JS, Byun KS, Bak YT (2013) The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats. Mol Med Rep 7:1267–1272
31. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781
32. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989–1998
33. Keller J, Schinke T (2013) The role of the gastrointestinal tract in calcium homeostasis and bone remodeling. Osteoporos Int 24:2737–2748
34. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25
35. Sharara AI, El-Halabi MM, Ghaith OA, Habib RH, Mansour NM, Malli A, El Hajj-Fuleihan G (2013) Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism 62:518–526
36. Wren TA, Shepherd JA, Kalkwarf HJ, Zemel BS, Lappe JM, Oberfield S, Dorey FJ, Winer KK, Gilsanz V (2012) Racial disparity in fracture risk between white and nonwhite children in the United States. J Pediatr 161:1035–1040
37. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009) Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 104(Suppl 2):S27–S32
38. El-Serag HB, Richardson P, Pilgrim P, Gilger MA (2007) Determinants of gastroesophageal reflux disease in adults with a history of childhood gastroesophageal reflux disease. Clin Gastroenterol Hepatol 5:696–701